Abstract: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

Abstract: A breath actuated metered dose inhaler including a housing, a mouthpiece positioned at one end of the housing, and a mechanical release mechanism positioned at another end of the housing. The release mechanism is triggered by a diaphragm and the inhaler is configured such that the air inhalation pathway is unimpeded by the release mechanism.

Abstract: A nasal drug delivery system and method of delivering a predetermined amount of medication to the nasal epithelia. The system including a container containing a substance to be delivered into the nasal passages of a user. The nasal drug delivery system also includes a nasal shaft extending from the drug delivery system for placement in or around the nose of user, the nasal shaft is in fluid communication with a valve of the container, and an oral shaft, extending from the drug delivery system for placement in the mouth of a user. The nasal drug delivery system also comprises a pressure activated diaphragm trigger, wherein upon application of pressure to the oral shaft triggers the release of a predetermined amount of a substance from the container to the nasal shaft.

Abstract: A breath actuated metered dose inhaler including a housing, a mouthpiece positioned at one end of the housing, and a mechanical release mechanism positioned at another end of the housing. The release mechanism is triggered by a diaphragm and the inhaler is configured such that the air inhalation pathway is unimpeded by the release mechanism.

Abstract: This invention relates to a medicinal aerosol suspension formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug or a combination of at least two particulate drugs, a propellant and a stabilizing agent comprising a water addition.

Abstract: A method of treating a systemic disease in a patient in need of such treatment is disclosed. The method comprising maintaining the inspiratory flow rate and volume of the patient to a certain value and then administering a medicament aerosol formulation to such patient.